Anna Brusch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Anna Brusch has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Christine Bundell
PathWest and Department of Clinical Immunology, Sir Charles Gairdner Hospital, Nedlands, Australia
1 shared publicationPeter Hollingsworth
PathWest and Department of Clinical Immunology, Sir Charles Gairdner Hospital, Nedlands, Australia
1 shared publication
Latest Publications
- Open Access
- 8 June 2016
- Published by MDPI AG in Antibodies
- Vol. 5 (2) , 16
The Significance of Anti-Beta-2-Glycoprotein I Antibodies in Antiphospholipid Syndrome
Antiphospholipid syndrome (APS) is a thrombophilic disorder that classically presents with vascular thrombosis and/or obstetric complications. APS is associated with antiphospholipid antibodies: a heterogeneous group of autoantibodies that are directed against membrane phospholipids in complex with phospholipid-binding proteins. Beta-2-glycoprotein I (B2GPI) binds anionic phospholipids and is considered to be the predominant antigen in APS and antibodies against B2GPI (anti-B2GPI) are recognised in the laboratory criteria for APS diagnosis. This review focuses on the part played by anti-B2GPI in the pathogenesis of APS, their associations with different clinical phenotypes of the disorder and new avenues for refining the diagnostic potential of anti-B2GPI testing.
- 8 June 2016
- Published by MDPI AG in Antibodies
- Vol. 5 (2) , 16
Open AccessThe Significance of Anti-Beta-2-Glycoprotein I Antibodies in Antiphospholipid Syndrome
Antiphospholipid syndrome (APS) is a thrombophilic disorder that classically presents with vascular thrombosis and/or obstetric complications. APS is associated with antiphospholipid antibodies: a heterogeneous group of autoantibodies that are directed against membrane phospholipids in complex with phospholipid-binding proteins. Beta-2-glycoprotein I (B2GPI) binds anionic phospholipids and is considered to be the predominant antigen in APS and antibodies against B2GPI (anti-B2GPI) are recognised in the laboratory criteria for APS diagnosis. This review focuses on the part played by anti-B2GPI in the pathogenesis of APS, their associations with different clinical phenotypes of the disorder and new avenues for refining the diagnostic potential of anti-B2GPI testing.